Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In Process Receivables - Net Shares Outstanding Shares Outstanding Shares Repurchased

Tandem Diabetes Care (TNDM) Shares Issued (2016 - 2024)

Tandem Diabetes Care filings provide 12 years of Shares Issued readings, the most recent being $2.3 million for Q4 2024.

On a quarterly basis, Shares Issued fell 12.04% to $2.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$6.7 million, a 260.85% decrease, with the full-year FY2024 number at -$6.7 million, down 260.85% from a year prior.
Shares Issued hit $2.3 million in Q4 2024 for Tandem Diabetes Care, up from -$4.5 million in the prior quarter.
In the past five years, Shares Issued ranged from a high of $28.6 million in Q2 2020 to a low of -$25.7 million in Q3 2020.
Median Shares Issued over the past 5 years was $15000.0 (2020), compared with a mean of $971842.1.
Biggest five-year swings in Shares Issued: soared 1738700.0% in 2022 and later crashed 3481.25% in 2023.
Tandem Diabetes Care's Shares Issued stood at $15000.0 in 2020, then crashed by 106.67% to -$1000.0 in 2021, then soared by 1738700.0% to $17.4 million in 2022, then tumbled by 84.95% to $2.6 million in 2023, then fell by 12.04% to $2.3 million in 2024.
The last three reported values for Shares Issued were $2.3 million (Q4 2024), -$4.5 million (Q3 2024), and -$3.0 million (Q2 2024) per Business Quant data.